

Carbon-Vivo LTD

Volume of investments required: \$ 400 thousand

Intended use of investment required:

R&D (design work of artificial heart valves)	10%
Fixed assets acquisition (for artificial heart valve)	70%
Marketing (artificial heart valves)	20%

Company profile:

1. Date of establishment - December 29, 2003
2. Stage of development - Start-Up
3. Size and source of investment to date - \$ 60 th. - authorized (charter) capital
4. Industry - Medical technical, manufacture of the artificial heart valves
5. Target market - Cardiosurgery
6. Sales in 2003 - None
7. Description and value of assets - None
8. Intellectual property rights - draw up the claim for patent Russia (Three-leaflet artificial heart valve, Agafonov A.V., Kouznetsov V.O)

Owners:

2 natural persons	50% each other
Share of government property	0%

Management and key personnel:

Bogaturev Michail Grigorievich - the general director, 47, In 1996-1997 in a post of the Vice-president and President has organized and licensed in Federal Committee of Securities Russian Federation the investment company JSC Meta- Invest Service », afterwards of largest shareholder JSC "Altai-coke". The experience of commercialization of scientific development has no.

Agafonov Andrei Vasilievich - the leader of project, 59, Ph.Dr., the author more than 70 publications both patents in the field of a research and development of artificial heart valves, winner of the premium Council Ministers USSR for development of small-sized artificial valves of heart, general director CJSC "TRI Carbon" (Moscow), enterprise attends to production Pyrolitic materials for manufacturing artificial heart.

Products characteristics:

Three leaflet artificial heart valve is intended for implantation instead of the hit natural valve. The implantation of artificial heart valves is coming in sharp improving of quality life of the patients, the hard working is restored, the physical inability is removed, women even can have children. In an outcome of implantation of the new valve on it an output the central stream of blood with a low level of tangents tension a Level haemolysis, created by work of the valve will be formed, should be much lower, than at nowadays used in cardiology of two leaflet valves. It is supposed, that the new three leaflet valve will allow to improve outcomes of operations and to reduce a level post operative anticoagulation therapy. On the functional performances the new valve exceeds all existing analogs.

Comparative analysis with existing alternatives:

Characteristics	Three leaflet valve, 2006-	"Meding Ltd.", Russia 1996	"Roscardioinvest Ltd", Russia MIKS ROSCARDICS,	ST.JUDE MEDICAL, INC. USA,
-----------------	----------------------------	----------------------------	--	----------------------------

	plan output into market		2001	1998
Amount of standard sizes	10			
Stroke volume, SM3	40 - 100			
Regurgitation, SM3	5 - 12			
Life time, year, no less than	25	20	20	20
Characteristic constant of time. Dependent from destructive ability of the valve, sec.	120 10,5	60 7,3	50 7,3	65 8,5
Availability of central not infringed flow of the blood through the valve.	Yes	No	No	No
Cost of operation, \$	About 10 000			

The availability of the central not infringed stream of blood through the valve will allow qualitative to change of the post operative period at the expense of decrease of dependence from anticoagulation therapy. The magnification characteristic component of time decrease of a level haemolysis, i.e. about decrease of a level of destruction of elements of blood.

Markets/Competition:

	Characteristics	Products/services of exhibiting company	"Meding Ltd.", Russia	"Roscardioinvest Ltd", Russia	St. Jude Medical, Inc, USA
	Geographical Region - Russia+ CIS Market size \$ 4,500 th.				
2004	Company market share, \$ ths./%	0	2 500 / 55,6%	1 600 / 35,6%	400 / 8,8%
	Geographical Region - Russia+ CIS Market size \$ 8,500 th.				
2008	Company market share, \$ ths./%	2 200 / 25,8%	3 200 / 37,6%	2 200 / 25,8%	900 / 10,%

The requirement for operations on a replacement of the valve of heart in Russia makes about 200,000 per one year. In 2002 were making about 5,000 operations. The growth of an amount of operations makes about 800 operations per one year. (Data by Bakulev scientific center for cardiovascular surgery). The cost of one domestic valve makes about \$ 500, and foreign up to \$ 2,000 (for identical quality).